Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032784 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
A Phase 4 study, sponsored by AdventHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT02032784: Clinical Trial Phase 4 study, sponsored by AdventHealth.
NCT02032784 is a Phase 4 study that was terminated before completion, run by AdventHealth. The registered enrollment target is 33 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02032784, a Phase 4 study, was terminated before completion, sponsored by AdventHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.
Primary Outcome
clinical evidence of a bleed, including melena, hematochezia, hematemesis
Interventions
- DRUG octreotide
- OTHER No Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-03 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 4 |
Why NCT02032784 stopped before completion
NCT02032784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which octreotide is the first listed.
NCT02032784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02032784 about?
NCT02032784 is a clinical study titled "Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding". Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.
What is the current status of trial NCT02032784?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2014-03. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT02032784?
The interventions under investigation include: octreotide (DRUG), No Octreotide (OTHER).
Who is sponsoring clinical trial NCT02032784?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02032784's enrollment target sits among peer trials
33 1528th of 2000 higher than 467 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia